Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Relapsing-Remitting Multiple Sclerosis
NCT00207727Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2004
- Primary completion
- Mar 2006
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of ustekinumab in relapsing-remitting multiple sclerosis (RRMS) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Cumulative Number of Newly Gadolinium-enhancing T1-weighted Lesions on Cranial Magnetic Resonance Imaging (MRI)s at Week 23. Started Jul 2004; status: completed.
02
Drugs
ustekinumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00207727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00207727.